On Monday, Tilray, Inc. TLRY reported an 8% sequential drop in the second quarter net revenue to $155 million. Year-over-year, net revenue increased 20%.
Total cannabis revenue saw a 16% quarter-over-quarter decline to $58.8 million, well below the FactSet consensus estimate of $66.6 million and the projections that Cantor Fitzgerald's Pablo Zuanic disclosed last week.
Tilray also reported a 29% decrease in domestic recreational sales.
Zuanic called this drop "significant," even though the management earlier warned that destocking by the boards/wholesalers would result in reported sales "coming in below underlying retail trends."
In his previous note, the analyst identified a 16% drop in recreational sales in the November quarter in a market that grew 5% over the same period as one of the three "true sentiment drivers," besides stable export trends and cannabis gross margins that "may be down due to operating deleverage and ongoing price deflation."
And while "exports were better than expected," said the analyst, being up 33% on a sequential basis from $10.3 million in the previous quarter, the "rec number and gross margins are both disappointing," considering that gross margin for the cannabis business fell to 23% from 43% in the prior period.
Nevertheless, Zuanic said that the quarter-over-quarter "bump" in exports "should be seen as good news if sustained."
"We stay Neutral and would expect the stock to see some pressure today," Zuanic concluded.
The analyst lowered his 12-month price target to $7.40 from $11.80 while maintaining a Neutral rating on Tilray's stock last week.
In the meantime, the Canadian marijuana giant also announced a new parent name, Tilray Brands, Inc., reflecting the company's evolution from a Canadian LP to a global consumer packaged goods company with a portfolio of cannabis and lifestyle CPG brands.
TLRY Pirce Action
Tilray's shares traded 11.37% higher at $7.15 per share at the time of writing on Monday morning.
Photo: Courtesy of Tima Miroshnichenko from Pexels
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!